Waziry R, et al. – Objectives of this meta–analyses were to compare the rate of hepatocellular carcinoma (HCC) occurrence following direct–acting antiviral (DAA) vs. interferon (IFN)–based cure in patients with hepatitis C virus (HCV)–related cirrhosis and to compare the rate of HCC recurrence following DAA vs. IFN–based cure in patients who received curative HCC treatment. In this systematic review, the physicians found no evidence for differential HCC occurrence or recurrence risk following sustained virological response (SVR) from DAA and IFN–based therapy.